Bristol-Myers Squibb
Taxane Chemotherapy(Bristol-Myers Squibb)은 HER2 표적 ADC로, HER2 + Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: target because it is enriched in high-grade serous ovarian carcinoma, is relatively shielded from circulating drugs in many polarized normal epithelia, and undergoes receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 81.1% (ClinicalTrials.gov NCT00455533). 차별점: novel anti-chemoresistance treatments.
HER2
HER2 + Breast Cancer
Recruiting
CAR-T cells have shown biological feasibility without consistentl
release
linker-payload technologies
lipid nanoparticle (SLN) system designed to enhance the codelivery of PTX and Q to αvβ
novel anti-chemoresistance treatments
target because it is enriched in high-grade serous ovarian carcinoma, is relatively shielded from circulating drugs in many polarized normal epithelia, and undergoes receptor
payload release, ocular toxicity, P-glycoprotein efflux, tubulin-payload resistance, tumor-associated macrophages, regulatory T
biomarker, delivery portal, immune target and resistance-associated therapeutic axis
resistance to chemotherapeutic medications such as cisplatin and paclitaxel are frequent outcomes in ovarian cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Bristol-Myers Squibb
Taxane Chemotherapy(Bristol-Myers Squibb)은 HER2 표적 ADC로, HER2 + Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: target because it is enriched in high-grade serous ovarian carcinoma, is relatively shielded from circulating drugs in many polarized normal epithelia, and undergoes receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 81.1% (ClinicalTrials.gov NCT00455533). 차별점: novel anti-chemoresistance treatments.
HER2
HER2 + Breast Cancer
Recruiting
CAR-T cells have shown biological feasibility without consistentl
release
linker-payload technologies
lipid nanoparticle (SLN) system designed to enhance the codelivery of PTX and Q to αvβ
novel anti-chemoresistance treatments
target because it is enriched in high-grade serous ovarian carcinoma, is relatively shielded from circulating drugs in many polarized normal epithelia, and undergoes receptor
payload release, ocular toxicity, P-glycoprotein efflux, tubulin-payload resistance, tumor-associated macrophages, regulatory T
biomarker, delivery portal, immune target and resistance-associated therapeutic axis
resistance to chemotherapeutic medications such as cisplatin and paclitaxel are frequent outcomes in ovarian cancer
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.